Heavy Insider Selling at ADMA Biologics Despite Earnings Strength

ADMA Biologics, Inc. (NASDAQ:ADMA) is one of the 13 Best Low Risk High Growth Stocks to Buy.

The company witnesses significant insider sales amid strong growth and strategic advances reported in the Q1 earnings report.

Headquartered in New Jersey, ADMA Biologics, Inc. (NASDAQ:ADMA) is the only U.S.-based producer of plasma-derived immunoglobulin therapies. The company is engaged in the process of developing, manufacturing, and commercializing FDA-approved products, including ASCENIV, BIVIGAM, and Nabi-HB, to prevent and treat infectious diseases in immunodeficient and at-risk patients.

On May 7, 2025, the company reported its first quarter earnings report for 2025. With a solid 40% year-over-year increase in total revenues, reaching $114.8 million, the company raised its 2025 revenue guidance to more than $500 million. Additionally, the company has also announced a $500 million stock repurchase program, which reflects its confidence in its financial stability.

Later, on June 4, 2025, the company’s top executives started selling the company’s shares. Significant among them was the sales made by Director Steve Elms, who sold 425,621 shares, worth the value of $8,829,333.

Despite the potential hit these transactions could have had on the investor’s confidence, ADMA Biologics, Inc. (NASDAQ:ADMA)’s anticipated 5-year EPS growth continues to stand high at 39.37% while volatility remains low with a beta of 0.38.

While we acknowledge the potential of ADMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025

Disclosure. None.